Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments

Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments

Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory bowel disease (IBD). This acquisition underscores Lilly’s strategic expansion into the gastroenterology sector. The transaction, valued at $57 per share, is a significant premium over Morphic’s recent stock prices, reflecting […]

Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024

Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024

In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE: LLY) has revealed plans to inaugurate its first-ever Lilly Gateway Labs facility in San Diego, California, in the first half of 2024. This initiative marks the company’s third such facility, joining its existing sites in San Francisco […]

Lilly to acquire gene therapy firm Akouos to discover hearing loss treatments

Lilly to acquire gene therapy firm Akouos to discover hearing loss treatments

Lilly acquisition of Akouos : American pharmaceutical giant Eli Lilly and Company (Lilly) has agreed to acquire precision genetic medicine company Akouos in a cash deal worth about $487 million. Headquartered in Boston and founded in 2016, Akouos is focused on developing a portfolio of advanced adeno-associated viral gene therapies to treat inner ear conditions, […]

Lilly gets FDA EUA for bebtelovimab in mild-to-moderate Covid-19

Lilly gets FDA EUA for bebtelovimab in mild-to-moderate Covid-19

Eli Lilly and Company (Lilly) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for bebtelovimab for the treatment of mild-to-moderate Covid-19. According to Lilly, bebtelovimab is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2, which has also shown capability to neutralize against the Omicron […]

Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study

Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study

Eli Lilly and Company (Lilly) has entered into a partnership with managed care company UnitedHealth Group to carry out a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, Covid-19 infected individuals. Recently, bamlanivimab was granted emergency use authorization (EUA) from the US Food and Drug Administration for the treatment of Covid-19 patients having mild to moderate […]

Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly and Company (Lilly) for the treatment of mild to moderate Covid-19. Bamlanivimab has been authorized to be used in adults and pediatric patients, aged 12 years and older with a […]

Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies

Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies

Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. Currently, Lilly is studying various potential neutralizing antibodies for the prevention and/or treatment of the novel coronavirus as monotherapy or in combination. Through the collaboration, the two US pharma companies […]

Lilly begins phase 1 coronavirus antibody trial with LY-CoV555

Lilly begins phase 1 coronavirus antibody trial with LY-CoV555

Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed in a phase 1 clinical trial with the investigational antibody LY-CoV555 for the treatment of COVID-19. LY-CoV555 is the first antibody candidate to emerge from Lilly’s collaboration with AbCellera Biologics, which was announced in March 2020, with […]